Stevens-Johnson syndrome cost-effectiveness of therapy: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Stevens-Johnson syndrome}} | {{Stevens-Johnson syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{AHS}} | ||
==Overview== | ==Overview== |
Latest revision as of 20:25, 12 September 2018
Stevens-Johnson syndrome Microchapters |
Differentiating Stevens-Johnson Syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Stevens-Johnson syndrome cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Stevens-Johnson syndrome cost-effectiveness of therapy |
FDA on Stevens-Johnson syndrome cost-effectiveness of therapy |
CDC on Stevens-Johnson syndrome cost-effectiveness of therapy |
Stevens-Johnson syndrome cost-effectiveness of therapy in the news |
Blogs on Stevens-Johnson syndrome cost-effectiveness of therapy |
Risk calculators and risk factors for Stevens-Johnson syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anila Hussain, MD [2]
Overview
To date, the treatment of Stevens-Johnson Syndrome is mainly supportive